Objective To investigate the therapeutic effect of cinepazide maleate on patients with acute myocardial infarction and the effect on the hs-CRP and IL-6 level.Methods Retrospective analysis of clinical data of patients with acute myocardial infarction from August 2014 to May 2016 in the hospital, according to the treatment methods, they were divided into cinepazide treatment group and conventional treatment group.The therapeutic effect of two groups were observed, and the differences of inflammatory factors,heart rate variability and cardiac function were compared between the two groups before and after treatment.Results The clinical effective rate of cinepazide treatment group was 96.9%, which was significantly higher than that of the conventional treatment group 87.1%(X2=4.528,P=0.033);Before treatment, the levels of IL-6 and hs-CRP were not significantly different between the 2 groups (t=0.738,t=-0.132,P=0.231,P=0.448);after treatment, the cinepazide treatment group was lower than the conventional treatment group (t=7.706,t=8.291,P<0.01);Two groups of patients before treatment of heart rate variability levels have no significant difference (P>0.05),after treatment, the cinepazide treatment group's SDNN, SDANN, RMSSD and PNN50 (%) were higher than the control group (t=-6.299,t=-4.657,t=-7.744,t=-6.947,P<0.01);before treatment the level of SV, NT-proBNP,CTnI,SV and LVEF levels were had no significant differences between the 2 groups (t=0.036,t=0.687,t=0.057,t=0.085,P>0.05);after treatment, the cinepazide treatment group's SV and LVEF were higher than the control group (t=-5.992,t=-5.940,P<0.01), NT-proBNP, CTnI in the cinepazide treatment were lower than the conventional treatment group (t=57.370,t=17.407,P<0.01).Two groups of patients during the treatment showed no adverse reactions such as liver and kidney damage.Conclusion Cinepazide has better therapeutic effect on patients with acute myocardial infarction, it can significantly improve cardiac function and reduce hs-CRP and IL-6 level.%目的 观察桂哌齐特对急性心肌梗死(AMI)患者的治疗效果及对血清炎性因子(hs-CRP、IL-6)水平,心率变异性、心功能及心肌标志物的影响.方法 回顾性分析2014年8月-2016年5月北京市第一中西医结合医院急诊科治疗的急性心肌梗死患者150例的临床资料,根据其治疗方式分为对照组85例(常规治疗)和观察组65例(常规治疗加桂哌齐特静脉滴注).观察2组患者的治疗效果和不良反应发生率,比较2组治疗前后的血清炎性因子、心率变异性、心功能及心肌标志物的差异.结果 观察组总有效率为96.9%高于对照组的87.1%(X2=4.528,P=0.033);治疗后,2组IL-6、hs-CRP均低于治疗前(P<0.01),且观察组优于对照组(t=7.706、8.291,P<0.01);治疗后,2组的SDNN、SDANN、RMSSD和PNN50(%)高于治疗前(P<0.01),且观察组优于对照组(t=-6.299、-4.657、-7.744、-6.947,P<0.01);治疗后观察组SV和LVEF高于对照组(t=-5.992、-5.940,P<0.01),NT-proBNP、CTnl低于对照组(t=57.370、17.407,P<0.01);2组患者在治疗期间均无肝肾功能损害等不良反应发生.结论 桂哌齐特对急性心肌梗死患者有较好的治疗效果,可明显改善患者心功能、降低hs-CRP及IL-6水平,具有临床应用价值.
展开▼
